Fourth quarter 2025 results: Revenue of $1.16 billion, up 5% from Q4 2024 (up 4% on a constant curre...

ILMN

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Fourth quarter 2025 results: Revenue of $1.16 billion, up 5% from Q4 2024 (up 4% on a constant curre...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Illumina&#039;s Q4 2025 revenue increased 5% YoY to $1.16 billion, reflecting growth in clinical markets. The company expects 2026 revenues to rise 4%-6%, bolstered by its recent acquisition of SomaLogic. This momentum is fueling confidence as Illumina aims to enhance its genomic testing capabilities and product offerings, making it a key player in precision medicine.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Q4 2025 revenue of $1.16 billion, up 5% year-over-year.</li><li>Fiscal 2025 total revenue stable at $4.34 billion, flat from 2024.</li><li>2026 guidance anticipates revenue growth of 4%-6%, aided by SomaLogic.</li><li>Non-GAAP diluted EPS for Q4 2025 increased to $1.35.</li><li>Illumina enters 2026 with strong clinical market momentum.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>SomaLogic (SLGC)</strong>: Acquisition expected to boost ILMN&#039;s multiomics portfolio.</li><li><strong>AstraZeneca (AZN)</strong>: Partnering on AI-enabled drug discovery enhances Illumina&#039;s market relevance.</li><li><strong>Merck (MRK)</strong>: Involvement in drug discovery boosts potential customer base for ILMN.</li><li><strong>Eli Lilly (LLY)</strong>: Collaborations may enhance growth potential for genomic applications.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news fits into the &#039;Corporate Developments&#039; category, highlighting key financial results and strategic acquisitions that directly impact Illumina&#039;s market position and future growth prospects within the genomic testing landscape.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Revenue growth of 4%-6% projected for 2026 may boost investor sentiment.</li><li>Successful integration of SomaLogic can enhance product offerings and revenue potential.</li><li>Strong momentum in clinical markets drives confidence ahead of Q1 earnings.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Q4 2025 GAAP EPS was $2.16; non-GAAP EPS was $1.35.</li><li>FY 2025 revenue was flat at $4.34 billion.</li><li>SomaLogic acquisition expected to contribute 1.5%-2.0% growth in 2026.</li><li>Q4 2025 non-GAAP operating margin increased to 23.7%.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish on ILMN as 2026 growth prospects improve with clinical market expansion.</p>
  </section>
</section>


<article>
    <h2>Illumina (ILMN) Reports Financial Results for Q4 and Fiscal Year 2025</h2>
    <p>
        Illumina, Inc. (Nasdaq: ILMN) has released its financial results for the fourth quarter and fiscal year 2025, showcasing a robust recovery and growth trajectory. The company reported <strong>total revenue of $1.16 billion</strong> for Q4 2025, a <strong>5% increase</strong> compared to the same quarter last year. This performance reflects strong operational execution amid evolving market conditions, particularly in clinical markets where next-generation sequencing (NGS)-based testing continues to gain traction.
    </p>

    <h3>Fourth Quarter 2025 Highlights</h3>
    <ul>
        <li><strong>Revenue:</strong> $1.16 billion, a 5% increase from Q4 2024 (4% on a constant currency basis)</li>
        <li><strong>Ex-China Revenue:</strong> $1.10 billion, up 8% from Q4 2024 (7% on a constant currency basis)</li>
        <li><strong>GAAP Operating Margin:</strong> 17.4%</li>
        <li><strong>Non-GAAP Operating Margin:</strong> 23.7%</li>
        <li><strong>GAAP Diluted EPS:</strong> $2.16</li>
        <li><strong>Non-GAAP Diluted EPS:</strong> $1.35</li>
    </ul>

    <h3>Fiscal Year 2025 Performance</h3>
    <ul>
        <li><strong>Total Revenue:</strong> $4.34 billion, unchanged compared to 2024 (both reported and constant currency)</li>
        <li><strong>Ex-China Revenue:</strong> $4.10 billion, a 2% increase compared to 2024 (reported and constant currency)</li>
        <li><strong>GAAP Operating Margin:</strong> 18.6%</li>
        <li><strong>Non-GAAP Operating Margin:</strong> 23.1%</li>
        <li><strong>GAAP Diluted EPS:</strong> $5.45</li>
        <li><strong>Non-GAAP Diluted EPS:</strong> $4.84</li>
    </ul>

    <h3>Guidance for Fiscal Year 2026</h3>
    <p>
        Looking ahead, Illumina has set a positive outlook for fiscal year 2026, anticipating:
    </p>
    <ul>
        <li><strong>Total Revenue:</strong> Between $4.5 billion and $4.6 billion, representing growth of <strong>4% - 6%</strong> on a reported basis, with a 1.5% - 2.0% boost from the SomaLogic acquisition.</li>
        <li><strong>Ex-China Organic Revenue Growth:</strong> Expected growth of <strong>2% - 4%</strong>, excluding currency and acquisition impacts.</li>
        <li><strong>Non-GAAP Operating Margin:</strong> Anticipated in the range of <strong>23.3% - 23.5%</strong>, factoring in a negative impact of 100 basis points from the SomaLogic acquisition.</li>
        <li><strong>Non-GAAP Diluted EPS:</strong> Projected between <strong>$5.05 - $5.20</strong>, accounting for $0.18 in dilution from SomaLogic.</li>
    </ul>

    <h3>CEO Remarks on Growth and Strategy</h3>
    <p>
        Jacob Thaysen, Chief Executive Officer of Illumina, highlighted the company's strong quarterly results, stating, <em>"The Illumina team delivered a strong finish to 2025, marking a return to growth through disciplined execution against our strategy."</em> He emphasized the momentum gained in clinical markets, reinforcing confidence as the company advances into 2026.
    </p>

    <h3>Key Announcements and Developments</h3>
    <ul>
        <li>Finalized the acquisition of SomaLogic, enhancing Illumina's multiomics portfolio and capabilities in NGS-enabled proteomics.</li>
        <li>Launched the Billion Cell Atlas, the inaugural product of the BioInsight division, aimed at supporting AI-driven drug discovery.</li>
        <li>Appointed Eric Green, MD, PhD, as Chief Medical Officer to promote clinical genomics and broaden access to precision medicine.</li>
        <li>Secured progress in China as the export ban on Illumina sequencers was lifted by the Ministry of Commerce.</li>
    </ul>

    <h3>Conclusion</h3>
    <p>
        With its robust financial results for Q4 2025 and fiscal year 2025, Illumina (ILMN) exemplifies resilience within the biotech industry. The outlook for fiscal year 2026 appears promising, driven by strategic acquisitions and market expansion initiatives. Investors and stakeholders are keenly watching how these developments unfold in the coming year.
    </p>
</article>

Illumina's Q4 2025 revenue increased 5% YoY to $1.16 billion, reflecting growth in clinical markets. The company expects 2026 revenues to rise 4%-6%, bolstered by its recent acquisition of SomaLogic. This momentum is fueling confidence as Illumina aims to enhance its genomic testing capabilities and product offerings, making it a key player in precision medicine.

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News